Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop.

["Chen, Xiaowei", "Deng, Huan", "Churchill, Michael J", "Luchsinger, Larry L", "Du, Xing", "Chu, Timothy H", "Friedman, Richard A", "Middelhoff, Moritz", "Ding, Hongxu", "Tailor, Yagnesh H", "Wang, Alexander L E", "Liu, Haibo", "Niu, Zhengchuan", "Wang, Hongshan", "Jiang, Zhengyu", "Renders, Simon", "Ho, Siu-Hong", "Shah, Spandan V", "Tishchenko, Pavel", "Chang, Wenju", "Swayne, Theresa C", "Munteanu, Laura", "Califano, Andrea", "Takahashi, Ryota", "Nagar, Karan K", "Renz, Bernhard W", "Worthley, Daniel L", "Westphalen, C Benedikt", "Hayakawa, Yoku", "Asfaha, Samuel", "Borot, Florence", "Lin, Chyuan-Sheng", "Snoeck, Hans-Willem", "Mukherjee, Siddhartha", "Wang, Timothy C"]
Cell stem cell 2017
Open on PubMed

Myeloid-biased hematopoietic stem cells (MB-HSCs) play critical roles in recovery from injury, but little is known about how they are regulated within the bone marrow niche. Here we describe an auto-/paracrine physiologic circuit that controls quiescence of MB-HSCs and hematopoietic progenitors marked by histidine decarboxylase (Hdc). Committed Hdc+ myeloid cells lie in close anatomical proximity to MB-HSCs and produce histamine, which activates the H2 receptor on MB-HSCs to promote their quiescence and self-renewal. Depleting histamine-producing cells enforces cell cycle entry, induces loss of serial transplant capacity, and sensitizes animals to chemotherapeutic injury. Increasing demand for myeloid cells via lipopolysaccharide (LPS) treatment specifically recruits MB-HSCs and progenitors into the cell cycle; cycling MB-HSCs fail to revert into quiescence in the absence of histamine feedback, leading to their depletion, while an H2 agonist protects MB-HSCs from depletion after sepsis. Thus, histamine couples lineage-specific physiological demands to intrinsically primed MB-HSCs to enforce homeostasis.